The Disney Cruise Line was started when Disney executives decided to bring the unique style of Disney entertainment to the cruise industry. Previously, Disney had a cooperative venture with Premiere Cruise Line's Big Red Boats, but they weren't completely happy because they couldn't control the entire experience. Disney wanted to be absolutely sure that any cruise that they put their name on was up to the standards of their parks. So, they created the Disney Cruise Line and built two ships called the Disney Magic and the Disney Wonder. The ships are estimated to cost 0 million each. Disney went with a beautiful design that captures the feel of the classic trans-Atlantic liners of early this century. Above decks, details abound from the Mickey Mouse ornamentation on the stem to our friends Goofy and Donald making the final touches to the fantail. Below decks, the ship is decorated in lush carpets and fine woods. Elegance with subtle and not so subtle touches of whimsy such as the Mickey Mouse hand pointer on the elevator floor indicator, the ship's whistle that plays "When You Wish Upon a Star" and the requisite hidden Mickeys in the dcor. You can easily imagine that you are on the Normandy or the Queen Mary sailing across the Atlantic Ocean. The Disney Magic had her maiden voyage on July 30, 1998 and the Disney Wonder began sailing on August 15, 1999. While the Disney Magic and the Disney Wonder look the same on the outside, there are a number of cosmetic differences. The floor plans remain the same, but the decor and themeing differs. Guests aboard the Disney Magic enjoy a classical art deco look to the decor with deep nautical colors. Guests aboard the Disney Wonder are treated to a art nouveau look giving the look and feel of old Paris which features sycamore wood, blue glass and polished nickel railings. The centerpiece of the atrium lobbies are statues of Mickey Mouse aboard the Magic and Ariel from The Little Mermaid aboard the Wonder. Many of the areas on the ships have been renamed. Aboard the Wonder, Lumiere's becomes Triton's the decor has been changed from the formality of the Beauty and the Beast theme to a more subtle color scheme with the colors of the sea, and a wall mosaic of King Triton ; , Beat Street becomes Route 66, Rockin Bar D becomes Wavebands, Off Beat becomes Barrel of Laughs, Sessions becomes Cadillac Lounge and Topsider Buffet becomes Beach Blanket Buffet. The Barrel of Laughs comedy club is also a brewpub. The Cadillac Lounge features mockups of classic cars for seating. While Goofy is preoccupied with painting the Magic's name on the transom, the honor goes to Donald and one of his nephews on the Disney Wonder. With the Magic's dry dock in September 2003 and the Wonder's in fall 2004, a few changes occurred: 1. The ESPN Skybox was converted to "Stacks" a teen club. 2. Off Beat Barrel of Laughs became "Diversions, " an Irish pub sports bar. 3. Common Grounds was converted to the Quiet Cove Caf, a gathering place for adults where you will find cognac, cigars, and specialty coffees. 4. Morty the Magician's show was retired to make way for "Golden Mickeys, " an academy awards show themed event. Michael Eisner, CEO of Disney has said publicly that he wants a fleet of ten ships eventually, so if the first ships continue to go well, we can expect an entire magical fleet. Many rumors keep surfacing about a third ship in the Disney Cruise fleet. DCL management states they'd love a 3rd ship but the Euro needs to be more dollar friendly before that will happen.
Local news: pottstown, pa change ; join the topix community today: sign up sign in 3 2 topix top picks nasa's phoenix lander discovers water on mars hardworking homeless: not as rare as you think man on greyhound bus stabs, decapitates passenger forums top stories popular local us world sports entertainment offbeat other topics topamax, topiramate forums & polls news newswire topamax, topiramate news news on topamax, topiramate generic ; continually updated from thousands of sources around the net.
22. VACCINATIONS: Please give dates for all the times you have been vaccinated Autogenous homologous ; Bacterial attenuated ; Bacterial killed ; Cholera Diphtheria Hemophilus Influenza type B HIB ; Hepatitis B Influenza please give all dates ; Mumps Pertussis whooping cough ; Pneumococcal vaccine Poliovirus oral live ; Rocky Mountain Spotted Fever Salk vaccine poliovirus inactivated ; TAB mixture of typhoid, paratyphoid A and paratyphoid B ; Typhoid ~ oral injection Viral hepatitis BCG bacilli Calmette-Gurin ; D.P.T. diphtheria, pertussis, tetanus ; Epidemic typhus fever Hepatitis given to new born infants ; Human Diploid Cell Rabies HDCV ; Measles live attenuated rubeola ; MMR measles, mumps, rubella German measles ; Plaque Poliovirus oral inactivated ; Rabies Sabin vaccine liver attenuated oral poliovirus ; Smallpox Tetanus Varicella chickenpox ; Yellow fever live attenuated.
Topiramate reduces anxiety
Inability of the patients to take sufficient drug amounts during the demanding 48-week treatment regimen. A complete analysis of how viral genetic diversity is related to SVR and other clinical variables will be presented elsewhere, but we have performed an initial characterization of how pretreatment HCV genetic diversity correlates with SVR. The pretherapy sequences were stratified as SVR or non-SVR, and then the total and unique numbers of variations relative to the population consensus reference sequence, the total Shannon's entropy values, and the mean genetic distances in the two groups were compared. For both genotype 1a and genotype 1b, the polyproteins of the SVR sequences were significantly more diverse than those of non-SVR samples at P 0.01. For genotype 1a, NS3 and NS5A were significantly more diverse in the SVR samples by at least three of the four analytical methods. For genotype 1b, core was significantly more diverse in SVR patients by all four measures, and E2, NS2, and NS3 were more diverse by three of the four measures. Therefore, our basic observation that pretherapy sequence diversity was higher in the day 28 marked responders than in the poor responders for a few select viral genes is also true when the sequences are analyzed with respect to the ultimate goal of therapy, SVR. Taking the data together, the focal distribution of viral genetic diversity at the patient level correlating with response to therapy and the inability of immune selection to account for all of this diversity lend strong support to the hypothesis that HCV genetic variation modulates efficacy of antiviral therapy in human patients. Because most of the reduction in viral levels at day 28 was due to peginterferon therapy, these data imply that the genes for which diversity differences correlate with early response to therapy function at least in part to blunt the type 1 interferon response in humans. This is consistent with the in vitro immune evasion activities reported for core, NS3, and NS5A 19 ; . The consistently higher diversity in isolates from the marked responders for whom the virus failed to counteract the drugs ; compared to the poor responders for whom the drugs were ineffective ; implies that the functions of the proteins which counteract the effects of therapy can be impaired by amino acid differences at multiple locations. In essence, diversity would correlate with clearance because there are only a few ways to optimize activity of the viral proteins but many ways to interfere with their function.
Gabapentin 600-3600 mg day none Neurontin Lamictal Lamotrigine 100-500 mg day none Topomax Topuramate 50-800 mg day none Benzodiazepines BDZs ; , namely clonazepam brand Klonopin ; and lorazepam brand Ativan ; may be used, especially in acute 11 manic episodes, to assist with mood control. See exhibit 5-5 for more information on BDZs. Atypical and typical antipsychotic agents may also be used for bipolar disorder, especially for manic stages of excitement. See exhibit 5-3 for more information.
Intermediate level audioconference will discuss issues involved in providing blood for both adult and pediatric patients in various settings. Issues in risk management and contract negotiation approval will also be discussed and ipratropium.
Avoid confusion with Toprol-XL metoprolol succinate ; by spelling out TOPAMAX topiramate ; on your prescription. Toprol-XL is a registered trademark of the AstraZeneca group of companies.
For the management of vasomotor symptoms associated with menopause, the usual dose is 0.3 mg to 1.25 mg daily in a cyclic regimen. Dosage may be increased to 2.5 mg or 3.75 mg daily if necesJournal of Managed Care Pharmacy 41 and tolterodine.
The drug is started at a low dose and increased slowly to avoid adverse effects. Psychiatric side effects occur in up to 23.9% of patients with epilepsy7 and are related to a personal or family history of psychiatric illness and rapid dose escalation. These psychiatric side effects include depression, anxiety, aggression, cognitive slowing, and psychosis. Topirramate has also been reported to precipitate psychosis in patients with schizophrenia8 and mood disorder.9 Case report. Mr. A, a 42-year-old man, was admitted to our Deaddiction Centre in January 2005 with a diagnosis of alcohol dependence syndrome according to ICD-10 criteria ; and presented with delirium tremens. The patient had a history of alcohol consumption for the last 15 years and had developed features of salience, tolerance, craving, and loss of control over drinking over the last 8 years. He presented with tremors; irritability; insomnia; loss of appetite; auditory, visual, and tactile hallucinations; disorientation; and clouding of consciousness, all of which began after 24 hours of abstinence. He had a history of possible withdrawal seizures in the past. There was no history of psychosis. There was a family history of alcohol dependence in his father and 2 male siblings. There was no family history of psychosis or mood disorder. Laboratory findings were within normal limits. The patient was started on a detoxification regimen with lorazepam, 16 mg per day PO in tapering doses, and vitamin supplementation. His withdrawal symptoms subsided within 48 hours, with hallucinations subsiding within 24 hours. After detoxification for 10 days, the patient was started on topiramate 25 mg per day as long-term medication for alcohol dependence. On the third day after starting topiramate, the patient suddenly awoke at around 1: 00 a.m., looked anxious, and reported that he could hear "voices calling out to him from hell" and discussing his death. He continued to hear these voices even after he was fully awake. He remained anxious, apprehensive, and distressed for the next 30 minutes and was sedated with intravenous haloperidol 10 mg and lorazepam 4 mg, both of which had to be repeated after 2 hours. During this episode, there was no disorientation, clouding of consciousness, or tremulousness. After topiramate was stopped, these psychotic symptoms remitted completely within 48 hours and did not recur. Toopiramate has been hypothesized to induce psychosis as a result of its antiglutamatergic properties in the nucleus accumbens and prefrontal cortex.8 Brief psychosis was the most common presentation in a series of patients with epilepsy.7 As patients with alcohol dependence syndrome show changes in glutamate receptors, especially during withdrawal, 6 they may be more sensitive to the effects of topiramate. To the best of our knowledge, this is the first report of topiramate precipitating psychosis in a patient with alcohol dependence. It is possible that patients presenting with alcohol withdrawal are more susceptible to this particular adverse effect.
Buy topiramate
He said most patients lost weight in the trial, but the changes did not reach statistical significance, primarily because of one outlier patient, and he does not believe the positive benefits seen with topiramate are due to the weight loss, "We think we see an effect that goes beyond weight change." Topramate Proof-of-Concept Trial in Neuropathy and acetazolamide.
18. Sofouglu M, Poling J, Mouratidis M, Kosten T. Effect of topiramate in combination with intravenous nicotine in abstinent overnight smokers. Psychopharmacology 2006; 184: 645-51. Garca Campayo J, Sobradiel N. Tabaco y psiquiatra Tobacco and psychiatry ; . Barcelona: Edikamed, 2008. 20. Cooney JL, Stevens TA, Cooney NL. Comorbility of nicotine dependence with psychiatric and substance-use disorders. In: Kranzler HR, Rounsaville BJ, Eds. ; . Dual diagnosis and treatment. New York: Marcel Deker; 1998, p: 22361. 21. Covey LS. Tobacco cessation among patients with depression. Prim Care 1999; 26: 691-706. Conde V, Escrib JA, Izquierdo J. Evaluacin estadstica y adaptacin castellana de la escala autoaplicada para la depresin de Zung. Arch Neurobiol 1970; 33: 281-303. Prochaska JO, Diclemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 1983; 51: 390. Ferrando L, Franco A, Bobes J. MINI International Neuropsychiatric Interview. Instituto IAP, Madrid, 1998. 25. Hughes JR, Hatsukami DK. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatr 1986; 43: 289-294. Jarvis M, Russell MAH, Salojee Y. Expired air carbon monoxide. A simple breath test for tobacco smoke intake. Br Med J 1980; 281: 484-5. Barrueco M, Jimnez C, Palomo L, Torrecilla M, Romero P, Riesco JA. Abstinencia puntual y continuada con el tratamiento farmacolgico del tabaquismo en la prctica clnica. Med Clin 2004; 123: 652-6. Domingo-Salvany A, Regidor E, Alonso J, Alvarez-Dardet C. Una propuesta de medida de la clase social. Aten Primaria 2000; 25: 350-63. Becoa E, Vazquez FL. The Fagerstrm test for Nicotine Dependence in a Spanish sample. Psychological Reports 1998; 83 3 Pt2 ; : 1455-1458. 30. Spielberger CD, Gorsuch RL, Lushene RE. Cuestionario de ansiedad estado rasgo. TEA 1968. Madrid. 31. Rubio G, Montero I, Juregui J, Martnez ml, lvarez S, Marn JJ. Validacin de la escala de impulsividad de Plutchik en poblacin espaola. Arch Neurobiol 1999; 61: 223-232. Vellisco A, Alvarez FJ, Elias T. Resultados de un programa psicofarmacolgico de deshabituacin tabquica tras 12 meses de seguimiento. Prev Tab 2003; 5: 510. Gordis L, Epidemiology. Philadelphia: Saunders, 1996. 34. Littell JH, Girvin H. Stages of change. A critique. Behav Modif 2002; 26: 22373.
Ortho-McNeil Pharmaceutical, Inc. provides the medical profession with prescription drugs in the following categories: Analgesics, anti-infectives, antiepileptics, cystic fibrosis and wound healing. The company's line of women's pharmaceuticals includes oral contraceptives, diaphragms, vaginal antifungals and hormone replacement therapy. Leading products include ULTRAM tramadol HCl ; pain medication; LEVAQUIN levofloxacin ; Antibacterial; TOPAMAX topiramate ; Antiepileptic; REGRANEX becaplermin ; Gel 0.01% for diabetic foot ulcers, and oral contraceptives such as ORTHO TRI-CYCLEN norgestimate ethinyl estradiol ; . Penaten develops, manufactures and markets a wide range of baby toiletries. The PENATEN brand is the market leader in Germany and enjoys a strong position in other European countries. Personal Products Company develops, produces and markets innovative oral health, women's health and sanitary protection products. It is a leader in the oral health market with a full line of floss, rinse and toothbrush products. Personal Products is also a leader in women's health products with nonprescription and prescription vaginal yeast cures, personal lubricants, urinary pain relief tablets and vaginal contraceptives. The company's comprehensive product line of sanitary protection products includes feminine incontinence products, pantiliners, tampons and maxi pads. RoC S.A. produces a line of products for the care of sensitive skin that includes lotions, cosmetics and creams for the face and body, and a sun protection line. The R.W. Johnson Pharmaceutical Research Institute conducts pharmaceutical research and development in therapeutic areas including anti-infectives, central nervous system, diabetes, hematology oncology, immunology inflammation, women's health, and wound healing. The Spectacle Lens Group designs, develops, manufactures and markets innovative ophthalmic lenses and bisacodyl.
Topiramate drug interactions
Half-life 413-415 ; . Some analyses of data from randomized controlled studies suggest topiramate may be the most potent of the new generation of AEDs 416 ; . Its mechanism of action remains unclear, but seems to involve blockade of voltage-sensitive sodium channels, increased GABA activity, and glutamate blockade via non-NMDA receptors. Preliminary clinical research has suggested that topiramate may also be useful in treating mania in patients with bipolar disorder, post-traumatic stress disorder, and frequent migraine and chronic daily headaches. 4.2.5. Tiagabine Tiagabine is one of few rationally designed AEDs in that it was designed based on the GABAergic theory of epilepsy Figure 7 ; . Tiagabine is a potent and selective inhibitor of the synaptosomal uptake of GABA, and it appears to lack benzodiazepine-like sedative effects. The drug is structurally related to nipecotic acid, but crosses the blood-brain barrier to a greater degree, being much more lipophilic. Tiagabine was approved in the U.S. in 1997 as an adjunctive therapy for patients 12 years of age or older with localization-related epilepsy. The inhibition of GABA reuptake allows increased binding of GABA to post-synaptic receptors, and the enhanced GABA activity may prevent propagation of seizure impulses 417 ; . However, it is unclear whether inhibiting GABA reuptake is the drug's only effect 418, 419 ; . 4.2.6. Vigabatrin Vigabatrin gamma-vinyl-GABA; Figure 7 ; is a close structural analog of GABA and operates as an enzyme-activated, irreversible inhibitor of GABA transaminase, an enzyme that degrades GABA 420 ; . Vigabatrin crosses the blood-brain barrier. Once bound to GABA transaminase, the drug is converted into a reactive intermediate that irreversibly inhibits the enzyme, resulting in dose-dependently increased levels of GABA in the brain 420, 421 ; . The product is a racemate, but only the S + ; enantiomer is pharmacologically active 422 ; . Nuclear magnetic resonance spectroscopy has demonstrated 2-3 fold increases in GABA concentration in the brains of adult epileptic patients treated with standard doses of vigabatrin 423 ; . Increased GABA concentrations are not only neuroprotective in theory, but extensive experimental evidence has shown that they do protect the brain against chemically and electrically induced convulsions 421 ; . The clinical development of vigabatrin was delayed in the U.S. by findings of microvacuolation in the white matter of brains in rodents and dogs. However, extensive monitoring in humans through autopsy, MRI, and cognitive function tests has confirmed that this does not occur in humans 424 ; . The FDA's external advisory committee has recommended vigabatrin Sabril ; for approval as an adjunctive therapy, but final action is still pending. The drug has been extensively used in more than 45 countries. 4.2.7. Zonisamide Zonisamide 1- 1, 2-benzoxazol-3-yl ; methanesulfonamide; Zonegran; Excegran; Figure 10 ; is a 1, 2benzisoxazole derivative and the first agent of this class to be developed as an AED. Zonisamide was launched in Japan as early as 1989. In various animal models, zonisamide has considerable activity. It appears to block 136.
Topiramate cognitive
BIPOLAR DISORDER 387. Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study. J Affect Disord 1997; 43: 151161 [B] 388. Lambert PA, Venaud G: [Comparative study of valpromide versus lithium as prophylactic treatment in affective disorders.] Nervure 1992; 5: 5765 French ; [B] 389. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455460 [E] 390. Stromgren LS: The combination of lithium and carbamazepine in treatment and prevention of manic-depressive disorder: a review and a case report. Compr Psychiatry 1990; 31: 261265 [E] 391. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE: Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148: 723725 [A] 392. Stevenson GH, Geoghegan JJ: Prophylactic electroshock; a fiveyear study. J Psychiatry 1951; 107: 743748 [B] 393. Geoghegan JJ, Stevenson GH: Prophylactic electroshock. J Psychiatry 1949; 105: 494496 [B] 394. Godemann F, Hellweg R: [20 years unsuccessful prevention of bipolar affective psychosis recurrence.] Nervenarzt 1997; 68: 582585 German ; [F] 395. Chanpattana W: Combined ECT and clozapine in treatment-resistant mania. J ECT 2000; 16: 204207 [G] 396. Decina P, Schlegel AM, Fieve RR: Lithium poisoning. NY State J Med 1987; 87: 230231 [G] 397. Kramer BA: A naturalistic review of maintenance ECT at a university setting. J ECT 1999; 15: 262269 [G] 398. Rhodes LJ: Maintenance ECT replaced with lamotrigine letter ; . J Psychiatry 2000; 157: 2058 [G] 399. Gupta S, Austin R, Devanand DP: Lithium and maintenance electroconvulsive therapy. J ECT 1998; 14: 241244 [G] 400. Barnes RC, Hussein A, Anderson DN, Powell D: Maintenance electroconvulsive therapy and cognitive function. Br J Psychiatry 1997; 170: 285287 [G] 401. Jaffe R, Dubin WR: Oral versus intravenous caffeine augmentation of ECT letter ; . J Psychiatry 1992; 149: 1610 [G] 402. Karliner W: Accidental convulsion induced by atropine. J Psychiatry 1965; 122: 578579 [G] 403. Clarke L: Psychiatric nursing and electroconvulsive therapy. Nurs Ethics 1995; 2: 321331 [F] 404. Kramer BA: A seasonal schedule for maintenance ECT. J ECT 1999; 15: 226231 [G] 405. Vanelle JM, Loo H, Galinowski A, de Carvalho W, Bourdel MC, Brochier P, Bouvet O, Brochier T, Olie JP: Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994; 10: 195205 [B] 406. Schwarz T, Loewenstein J, Isenberg KE: Maintenance ECT: indications and outcome. Convuls Ther 1995; 11: 1423 [B] 407. Gagn GG Jr, Furman MJ, Carpenter LL, Price LH: Efficacy of continuation ECT and antidepressant drugs compared to longterm antidepressants alone in depressed patients. J Psychiatry 2000; 157: 19601965 [B] 408. Kahn DA: The use of psychodynamic psychotherapy in manicdepressive illness. J Acad Psychoanal 1993; 21: 441455 [A] 409. Haas GL, Glick ID, Clarkin JF, Spencer JH, Lewis AB, Peyser J, DeMane N, Good-Ellis M, Harris E, Lestelle V: Inpatient family intervention: a randomized clinical trial, II: results at hospital discharge. Arch Gen Psychiatry 1988; 45: 217224 [A] J Psychiatry 159: 4, April 2002 Supplement 410. Clarkin JF, Carpenter D, Hull J, Wilner P, Glick I: Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr Serv 1998; 49: 531533 [A] 411. Miklowitz DJ, Goldstein MJ: Bipolar Disorder: A Family-Focused Treatment Approach. New York, Guilford Press, 1997 [G] 412. Miklowitz DJ, Simoneau TL, George EL, Richards JA, Kalbag A, Sachs-Ericsson N, Suddath R: Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 48: 582592 [A] 413. Basco MR, Rush AJ: Cognitive-Behavioral Therapy for Bipolar Disorder. New York, Guilford Press, 1996 [G] 414. Zaretsky AE, Segal ZV, Gemar M: Cognitive therapy for bipolar depression: a pilot study. Can J Psychiatry 1999; 44: 491494 [B] 415. Fava GA, Bartolucci G, Rafanelli C, Mangelli L: Cognitive-behavioral management of patients with bipolar disorder who relapsed while on lithium prophylaxis. J Clin Psychiatry 2001; 62: 556559 [B] 416. Cochran SD: Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol 1984; 52: 873878 [A] 417. Ehlers CL, Frank E, Kupfer DJ: Social zeitgebers and biological rhythms: a unified approach to understanding the etiology of depression. Arch Gen Psychiatry 1988; 45: 948952 [F] 418. Frank E, Hlastala S, Ritenour A, Houck P, Tu XM, Monk TH, Mallinger AG, Kupfer DJ: Inducing lifestyle regularity in recovering bipolar disorder patients: results from the maintenance therapies in bipolar disorder protocol. Biol Psychiatry 1997; 41: 11651173 [A] 419. Frank E, Swartz HA, Kupfer DJ: Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000; 48: 593604 [F] 420. Cole DP, Thase ME, Mallinger AG, Soares JC, Luther JF, Kupfer DJ, Frank E: Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. J Psychiatry 2002; 159: 116121 [A] 421. Frank E, Swartz HA, Mallinger AG, Thase ME, Weaver EV, Kupfer DJ: Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol 1999; 108: 579587 [A] 422. Colom F, Vieta E, Benabarre A, Martinez-Aran A, Reinares M, Corbella B, Gasto C: Topiiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001; 62: 475476 [G] 423. Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive Therapy of Depression. New York, Guilford, 1979 [G] 424. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES: Interpersonal Psychotherapy of Depression. New York, Basic Books, 1984 [G] 425. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 10931099 [A] 426. Weissman MM, Markowitz JC, Klerman GL: Comprehensive Guide to Interpersonal Psychotherapy. New York, Basic Books, 2000 [G] 427. Frank E, Kupfer DJ, Gibbons R, Houck P, Kostelnik B, Mallinger AG, Swartz HA, Thase ME: Interpersonal and social rhythm therapy prevents depressive symptomatology in patients with bipolar I disorder. Arch Gen Psychiatry in press ; [A] 428. Bauer MS, McBride L, Chase C, Sachs G, Shea N: Manual-based group psychotherapy for bipolar disorder: a feasibility study. J Clin Psychiatry 1998; 59: 449455 [B] 429. Rush AJ, Thase ME: Psychotherapies for depressive disorders: a review, in Evidence and Experience in Psychiatry, vol 1: Depressive Disorders. Edited by Maj M, Sartorious N. Chichester, UK, John Wiley & Sons, 1999, pp 161206 [G] and leflunomide.
Topamax and anxiety topiramate
If so, what? Are you allergic to fish, shellfish, iodine? Yes No Are you allergic to any medicine? Yes No If so, please list the medicine and reaction i.e. rash, anaphylaxis, nausea, hives, etc ; . Do you smoke? Yes No.
| Topiramate fact sheetReversible anorgasmia with topiramate therapy for headache: a report of 7 patients and etidronate.
N Cross Western New England Headache Clinic and Neurological Research Center, Bennington, VT, USA Topiramate at doses up to 100 mg bid mean 173 mg day ; was compared with placebo as a prophylaxis for episodic migraines. A total of 30 migraine patients with or without aura ; diagnosed according to IHS criteria participated in this 22-week study. Following a 4-week baseline period, patients received double-blind treatment at doses that were titrated over 6 weeks and maintained for an additional 12 weeks. At the start of double-blind therapy, topiramate-treated patients showed a trend toward a lower mean 28-day migraine frequency, the primary efficacy measure, compared with placebo 3.00 2.60 vs 3.78 1.99; P 0.10 ; . A similar trend was observed throughout the treatment period 2.63 2.54 vs 3.92 2.63; P 0.10 ; . The percentage of patients achieving a 50% or greater reduction in migraine frequency was significantly higher in the topiramate-treated group compared with placebo 46.7% vs 6.7%, P 0.035 ; . The 28-day migraine frequency during the final 10 weeks of treatment and the percentage of patients achieving a 50% or greater reduction in the frequency of migraines were secondary efficacy measures Eleven of the 15 patients in the topiramate group received treatment at the maximum daily dose of 200 mg. Four of the 7 patients who discontinued topiramate did so because of adverse events; the remaining 3 were for other reasons. In the placebo group, 6 patients discontinued: 3 for lack of efficacy and 3 for other reasons. Paresthesia, diarrhea, altered taste, and somnolence were the most common adverse events reported by patients in the topiramate group. The results of this small but controlled study suggest that topiramate is an effective prophylactic treatment in episodic migraine, although larger randomized, controlled studies are needed for validation.
Opiramate Topamax ; is a antiseizure medication which is also used in the management of migraine, depression, and neuropathic pain. Off label, it has gained popularity as a weight reduction agent, and used to treat bipolar disorders. In September 2001 a "Dear Healthcare Professional" letter was sent out indicating 21 cases of acute angle-closure glaucoma had been associated with the use of topiramate. The authors of this report reviewed 115 new cases of spontaneous ocular side effects associated with topiramate therapy. They identified 83 cases of bilateral and 3 cases of unilateral acute, secondary angle-closure glaucoma. Ages of the patients varied from 3 years to 70 years of age. Eighty-five percent of the cases occurred in the first 2 weeks of treatment. Five cases were precipitated within hours when their dose was doubled. The most prevalent presenting symptom 38 patients ; was blurred vision. All the findings of acute glaucoma such as ocular pain, headache, nausea and vomiting, pupillary changes, hyperemia, and corneal edema were reported. Management of this condition requires stopping topiramate, instilling a topical cycloplegic and beta-blocker, and giving an oral intraocular pressure-lowing and raloxifene.
|
Ligand stoichiometry, and suggests a dibasic bis-bidentate nature of the ligand, and hence the formation of ligand-bridged polychelates. This polymeric character is also reflected in the low solubility in water as well as in coordinating and non-coordinating organic solvents. Molecular weight and molar conductance measurements could not be made because of low solubility. The low values of specific conductance in DMF indicate the non-electrolytic nature of these complexes. The ligand structure was optimized using AM1 Hamiltonian using semi-empirical MO calculation software MOPAC [13]. The AM1 method was chosen among the various available methods in MOPAC because the present system contains too many nitrogen atoms and for such a system AM1 is more suitable [14]. The optimized minima are the true minima, as confirmed from Hessian calculations. The charges over the phenolic oxygen and azomethine nitrogen -0.2493 and -0.2314, respectively ; are more negative in comparison to other atoms of PH-B-PH, and suggest that these atoms are the coordinating atoms in the polymeric ligand. The electronic spectra of azobenzene and its derivatives are characterized by two bands; an intense absorption band ~ 104 ; due to the * transition and a weak to moderate absorption band ~ 600 ; due to the n * transition. The latter transition band sometimes overlaps with the strong * transition band [15]. The diffuse reflectance spectra of PH-B-PH and its Zn II ; polychelates show a band at 25000 and 22222 cm-1, corresponding to the * and n * transitions, respectively [15]. The observed shift.
Compounding topiramate suspension
Symptoms may require the adjunctive use of an antipsychotic medication. Side effects: Prominent side effects occur in up to 75% of patients and often include dystonia, thirst, polyuria, nausea, vomiting, tremor, fatigue, dizziness, weight gain and acne. 3 ; Lab monitoring: Renal and thyroid function tests, CBC, Calcium, and a pregnancy test is necessary before initiating lithium use. A baseline EKG may be obtained. Significant toxicity risk, hypothyroidism and renal damage are associated with lithium use. Laboratory monitoring of drug levels, thyroid panels and renal profiles need to occur a minimum of every 6 months. Valproate divalproex Depakote ; : 1 ; Efficacy: To date, there have been no double blind, placebo controlled studies of divalproex in children and adolescents though several show it's efficacy in adult bipolar disorders. Open studies show response rates in children and adolescents ranging from 60% to 83%. Another study shows divalproex to be equivalent to lithium in efficacy. 2 ; Side effects: Side effects occurring in 10% include headache, nausea, vomiting, diarrhea and somnolence. Weight gain is another potential side effect of concern. Toxicity in overdose is much less with divalproate than lithium. Rare though potentially fatal adverse events include irreversible hepatic failure primarily in infants toddlers ; , hemorrhagic pancreatitis shown in developmental disability population ; and agranulocytosis. 3 ; Lab monitoring: Baseline labs before initiating divalproate treatment need to include assessment for hepatic, hematologic and bleeding abnormalities. Hematolgic panels, hepatic profiles and drug levels are generally done at least every 6 months although this recommendation is not universally recommended by experts in bipolar treatment. Monitoring for clinical signs of these serious side effects is mandatory. Carbamazepine Tegretol ; : 1 ; Efficacy: Information regarding the use of carbamazepine in childhood bipolar disorder is limited to case reports. Its efficacy in adult bipolar disorders is well documented. 2 ; Side effects: Up to 50% of adult patients experience side effects. The most common dose related side effects are neurological, often transient and include diplopia, blurred vision, fatigue, nausea, vomiting, and ataxia. Less frequent side effects include skin rashes, mild leukopenia, mild thrombocytopenia, and hyponatremia rare in children ; . Mild liver enzyme elevations occur in 5-15%. Weight gain is also a concern. Rare though potentially fatal side effects of carbamazepine include thrombocytopenia, agranulocytosis, aplastic anemia, hepatic failure, exfoliative dermatitis i.e. Stevens Johnson syndrome ; , and pancreatitis. Carbamazepine may be fatal in overdose. 3 ; Lab monitoring: Routine blood monitoring does not reliably predict blood dyscrasias, hepatic failure or exfoliative dermatitis. Routine lab monitoring of drug level, hematolgic profile, and hepatic panel are routinely done at least every 6 months and immediately if clinical signs suggest serious side effects. Carbamazepine is an autoinducing agent, and therefore drug levels may decline over time. It also may increase or decrease the metabolism of several other medications. Atypical antipsychotics: While olanzapine is currently the only atypical antipsychotic with an FDA indication in the treatment of bipolar conditions, all of these agents have been used as primary or adjunctive treatment of bipolar conditions in children and adolescents. These agents, excluding clozapine, have the advantage of no mandatory lab monitoring. Hyperlipidemia, hyperglycemia, weight gain and sedation are risks with most of these agents, with the exception of ziprasidone. Patients on lithium who have psychotic features may be given atypical antipsychotics to effectively control the psychotic symptoms. However, the psychotic symptoms returned if the antipsychotic medication was discontinued in four weeks or less. Newer anticonvulsants: Many other anticonvulsants such as gabapentin, lamotrigine, oxcarbazepine, and topiramate are used in the treatment of bipolar conditions. Each has side effects and or warnings that need to be taken into account. To date, gabapentin and topiramate h are the ones that have data to support their efficacy in the treatment of bipolar conditions in children and adolescents and alendronate.
Baby was ill or weak, .1 You were ill or weak, .2 You produced insufficient milk, .3 You had a nipple or breast problem such as pain or dryness ; , .4 You did not want to pass dangerous things through breast milk such as alcohol, cigarette smoke, etc. ; , .5 Or some other reason? SPECIFY ; .6 CARD B-8 LEFT SIDE ; BABY WAS ILL OR WEAK: BABY HAD MEDICAL PROBLEM S ; THAT MADE IT DIFFICULT OR IMPOSSIBLE TO BE BREAST-FED. YOU WERE ILL OR WEAK: YOU HAD MEDICAL PROBLEM S ; THAT MADE IT DIFFICULT OR IMPOSSIBLE TO BREAST-FEED. YOU PRODUCED INSUFFICIENT MILK: FOR WHATEVER REASON, YOU DID NOT MAKE ENOUGH MILK TO MAINTAIN REGULAR BREAST-FEEDING. YOU DID NOT WANT TO PASS DANGEROUS THINGS THROUGH BREAST MILK: FOR EXAMPLE, MEDICATION S ; THAT YOU TAKE, CIGARETTE SMOKE, ALCOHOL, OTHER DRUGS. USE THIS CODE REGARDLESS OF WHETHER OR NOT YOU WERE EVER ADVISED NOT BREAST-FEED FOR THIS REASON.
Topiramate more for_patients
Have you seen the "Dear Doctor letter" that was sent out recently by Ortho-McNeil Pharmaceutical to ASHP and APhA members ; ? It states that there have been 23 cases of "a syndrome consisting of acute myopia associated with secondary angle closure glaucoma" in patients receiving topiramate Topamax ; . Here is a report about a different adverse reaction to topiramate. A recent letter in the American Journal of Psychiatry described three patients who became depressed while taking topiramate as a mood stabilizer.5 Topiramate has been used as an adjunctive mood stabilizer for a couple of years now. This is not an FDA-approved use. Three cases are presented, including a 24-year-old woman, a 34-year-old woman, and a 40-yearold woman. All of the patients had a previous history of bipolar disorder and topiramate was added to their regimens as an adjunctive medication for hypomanic symptoms. Within the first week, or when topiramate was increased to 50 mg daily, each of the women became depressed. Two of the patients reported severe depression and had suicidal ideation. The depression lifted within a few days to a week after the new agent was discontinued. The and calcitriol and Cheap topiramate online.
Male female age: 18-29 30-39 40-49 + type of seizures that you have: please identify any that you have if known ; not sure tonic-clonic gran-mal ; simple partial complex partial absence petit-mal ; acute repetitive 2 or more convulsions with in hours ; status epilepticus recurrent convulsions lasting more than 20 minutes ; when did your last seizure occur frequency of seizures daily weekly monthly yearly anticonvulsion medications taken: phenytoin dilantin ; valporate depakene ; phenobarbital primidone mysoline ; zorantin clonazepam klonopin carbamazrpine tegretol, carbatrol ; gabapentin neurontin ; lamotigine lamictal ; topiramate topamax ; not controlled by medication not sure of the name other do you experience short term memory loss.
The oceans are a unique environment, as challenging as outer space. Within the oceans are a range of extremes - high pressure; complex chemistry; turbulent boundary layers; a crucial interface with the atmosphere for the transfer of gases, particulates, heat, and momentum. Our understanding of the oceans on a global scale and our ability to probe their interior depends on the details of a wide range of physical and chemical processes and phenomena that include - gas transfer; the equation of state; the physics of bubbles; turbulent mixing in the ocean interior and at its boundaries; the propagation of sound and ocean optics. This session will invite papers that describe our understanding of these physical and chemical processes, and the potential for their exploitation and risedronate.
Overall, this review of the pharmacologic treatment of ED presents a very mixed picture. For patients with BN, antidepressant medication is a well-tested and widely-used treatment option. Provocative new ideas, such as the use of topiramate and ondansetron, are also being examined. For patients with AN, the absence of convincingly demonstrated pharmacologic options is quite disappointing, given the severity of this illness and the range of drug treatments shown to be effective in related disorders. New efforts focusing on relapse prevention and on the use of novel antipsychotics will, we hope, prove more fruitful. There is growing evidence that the symptoms of BED are medication-responsive, but the roles of both pharmacotherapy and psychotherapy in the treatment of this syndrome need further definition.
Bined with unique local regulatory requirements and variations in the interpretation and implementation of International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH ; guidelines, has served to set Japan apart from other regions.[3, 4] Across Asia, various English-speaking, motivated work forces are poised and well-suited to meet the needs of drug development sponsors. To support this, most of the region's leading specialists have received postgraduate medical training in the US or UK. Since per-subject trial costs are significantly lower in some Asian countries than they are in Japan, overall cost savings by including nonJapanese Asian countries in global clinical trials promise to be substantial. For example, one report says that the average persubject trial cost in Japan was more than $US20 000, whereas the.
1. Scope and Purpose A number of changes have been made to the provisions in part 208 2 1 CFR part 208 ; to reflect the narrowrd focus of this final regulation in response to section 601 of the Appropriations Act, and to clarify its purpose and scope. Section 208.1 a ; has been changed to indicate that the final regulation does not cover voluntarily distributed patient information for most prescription drugs, but rather covers products of "serious and significant concern." The phrase "that FDA determines pose a serious and significant public health concern requiring distribution of FDA-approved patient information" was added to 208.1 a ; to accomplish this change. Section 208.1 a ; of the 1995 proposed rule stated that the requirements applied to products "administered primarily on an outpatient basis without direct supervision by a health professional." FDA has changed the term "administered" in this context to the term "used." because.
Topiramate side effects dose
That topiramate can be considered a relatively safe drug that is potentially effective in the treatment of TN. Also our data suggest that small doses than previously tried in other studies can be used and the progressive increasing doses schedule may be efficient and may enhance tolerability to this drug. REFERENCES.
Disputing Psychiatry's Redefinition TO THE EDITOR: The APA Commission on Psychotherapy by Psychiatrists has major points of disagreement with the redefinition of psychiatry put forward by Jeffrey A. Lieberman, M.D., and A. John Rush, M.D. 1 ; . Drs. Lieberman and Rush outline a residency that would eliminate substantive training in skills essential to the basic psychological understanding and management of patients, as well as the complexities of psychotherapy. Drs. Lieberman and Rush have highlighted the economic forces driving many of today's medical decisions. We are all struggling to do more with less. The authors have seen in this struggle a need to redefine our specialty and our patient population by extending our specialty to include all patients, including those in neurology and internal medicine who have behavioral disturbances. Residents would spend 1 year in general medicine and a second year focused on neurological dis and buy ipratropium.
Daniel M. Ninio, Research Fellow, Department of Clinical Pharmacology, Alfred Hospital, Melbourne.
Creatinine clearance for all patients must precede administration of the first dose of dofetilide. For detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION. The risk of dofetilide induced ventricular arrhythmia was assessed in three ways in clinical studies: 1 ; by description of the QT interval and its relation to the dose and plasma concentration of dofetilide; 2 ; by observing the frequency of TdP in TIKOSYN treated patients according to dose; 3 ; by observing the overall mortality rate in patients with atrial fibrillation and in patients with structural heart disease. Relation of QT Interval to Dose: The QT interval increases linearly with increasing TIKOSYN dose see Figures 1 and 2 in CLINICAL PHARMACOLOGY: Dose-Response and Concentration Response for Increase in QT Interval ; . Frequency of Torsade de Pointes: In the supraventricular arrhythmia population patients with AF and other supraventricular arrhythmias ; the overall incidence of torsade de pointes was 0.8%. The frequency of TdP by dose is shown in Table 4. There were no cases of TdP on placebo.
Subjective responses. At the higher dose of fluoxetine tested 60 mg day ; , the investigators found significant changes in median scores from baseline to endpoint for several subscales of the EDI, including bulimia uncontrollable overeating, body dissatisfaction, drive for thinness, and ineffectiveness, but not for the perfectionism, interpersonal distrust, or interoceptive awareness subscales. Median changes on each of the subscales of the EAT also indicated significant reductions. Clinical studies have also supported the use of antidepressants such as desipramine13 and fluvoxamine14 in the treatment of bulimia nervosa, but have not often addressed underlying psychological factors. A study of d-fenfluramine found it to be statistically no better than placebo in 43 bulimia patients who also received psychotherapy.15 Despite moderate success with medication, bulimia continues to be a chronic, relapsing illness. The effectiveness of medication, particularly the TCAs, has been limited by side effects weight gain, drowsiness, and arrhythmias ; .16, 17 Topiramate, a broad-spectrum antiepileptic drug currently approved as adjunctive therapy in various forms of seizure disorders, has been shown to have efficacy in the treatment of binge-eating disorder in a case series and a recent randomized clinical trial18, 19 and has also shown efficacy in the management of patients with bulimia nervosa in case studies.2022 We now report secondary outcome measurements from a randomized, placebocontrolled trial23 of topiramate in patients with bulimia nervosa, including the examination of pathologic eating attitudes and behaviors. Results of primary efficacy analyses and additional details of methodology appear in a previous report.23 METHOD Study Design Patients were enrolled and treated as outpatients either at the University of Utah Health Sciences Center in Salt Lake City or at Mountain West Clinical Trials in Boise, Idaho. Study procedures were reviewed and approved by the respective institutional review boards for each site. After receiving a full explanation of the study procedures and possible side effects, patients signed an informed consent statement. Eligible patients underwent a 2- to 4-week screening and washout phase during which baseline values for bingeing and purging behaviors were established. Patients who met the entrance criteria were randomly assigned to receive topiramate or placebo according to a 1: ratio. Study medication was provided as 25-mg or 100-mg tablets of topiramate and matching placebo. All study medication was identical in appearance. Topiramate was started at 25 mg day for the first week, and patients were then titrated by 25 to mg week until the maximum tolerated dose, complete or near-complete efficacy.
Topiramate and zonisamide
Discontinuation of long-term treatment with clonidine, and the like, may precipitate manic episodes, and these conditions should be avoided whenever possible. Furthermore, as noted earlier, insomnia, or simply voluntarily going without sleep, may also precipitate a manic episode, and consequently, good sleep hygiene should be promoted. Recently it has been shown that cognitive behavioral therapy may, when used in conjunction with preventive pharmacologic treatment, reduce the frequency of breakthrough episodes. The mechanism here is not clear, and it also must be kept in mind that no form of psychotherapy is effective for either acute or continuation treatment of mania. Depressive Episodes Acute Treatment. When a depressive episode occurs in a patient with bipolar disorder the first step in the acute phase of treatment is to ensure that the patient is taking an antimanic drug, such as lithium, valproate, or carbamazepine, in a dose that would be effective in the acute treatment phase of mania. If the depression is not severe, one may want to wait 2 or 3 weeks to see if the depressive symptoms begin to clear, as this may often happen when one of these three agents is used. When depressive symptoms persist or when they are so severe to begin with that one cannot wait, one may add an antidepressant or consider adding lamotrigine or perhaps topiramate. Traditionally an antidepressant has been used; however, though effective, all the antidepressants entail the risk of precipitating a manic episode; a strategy for choosing and utilizing an antidepressant is discussed in the chapter on major depression. Neither lamotrigine nor topiramate carry a risk of inducing a manic episode, and between the two, the evidence for the effectiveness of lamotrigine is much stronger. In mild cases of depression, one may also consider the use of cognitive-behavioral therapy. Continuation Treatment. Once the depressive symptoms are relieved, treatment should be continued until the patient has been asymptomatic for a significant period of time. If an antidepressant were added to a mood stabilizer, one should probably consider discontinuing the antidepressant after the patient has been asymptomatic for a matter of months. Given the ongoing risk of a "precipitated" mania, it is preferable to discontinue the drug as soon as possible: if depressive symptoms recur, one may always restart it. In the case of topiramate or lamotrigine, the optimum duration of continuation treatment is not clear. Prudence suggests that if one knows, from history, how long the patient's depressive episodes tend to last, that treatment be continued somewhat past the expected date of spontaneous remission of the depression. Preventive Treatment. Lithium, carbamazepine and lamotrigine are all effective in preventing future depressive episodes. Preventive treatment with antidepressants in bipolar disorder is generally not justified, given the ongoing risk of precipitating a manic episode. Bipolar women currently in the preventive phase of treatment may often be safely managed into and through a planned pregnancy. Preventive treatment may be continued up to a few days before conception is attempted. If conception does not occur, preventive treatment is restarted and continued until the couple again wishes to conceive. Once conception does occur, preventive treatment is withheld, to be restarted immediately upon delivery; indeed, barring obstetric complications, it should be restarted within hours. In collaboration with the obstetrician, adjunctive treatment is then made available should manic symptoms appear. In cases where the risk of a relapse of mania is high and outweighs the risk to the fetus, one may consider restarting a mood stabilizer after the first trimester. With regard to breast feeding, no firm advice can be given: although maternal use of lithium, valproate and carbamazepine have all been rarely associated with adverse effects in breast-fed infants, large, controlled studies are lacking. Consequently the decision to breast feed or not should be made in light of the entire clinical picture, including the mother's illness and response to treatment. Substance Use. As noted earlier, alcohol abuse or alcoholism and cocaine addiction are not infrequently associated with bipolar disorder, and these must also be treated. Other Treatment Considerations Pregnancy. Pregnancy constitutes a special challenge in the treatment of bipolar disorder. None of the mood stabilizers are safe during pregnancy especially the first trimester ; . First generation antipsychotics, such as haloperidol, are probably less teratogenic; the teratogenic potential of olanzapine is not as yet clear. If mania does occur during pregnancy, then the risks to the fetus must be carefully weighed against the risks inherent in a manic episode. ECT should be carefully considered given that, with proper anesthetic technique, it is of low risk to the fetus.
Topiramate release date
Topiramate scar
Topirsmate, topiramatr, 6opiramate, yopiramate, topitamate, topuramate, topiramqte, topigamate, topiramat, topiramare, topi4amate, topriamate, topirzmate, topidamate, topiramatee, tpiramate, topiramste, topiramat3, topiramte, topiramahe, topirqmate, toipramate, topiramage, topiamate, topiramae, tpoiramate, topi5amate, topirakate, topjramate, topiraate, toppiramate, toliramate, topiramats, topiramaate, topiramatte, opiramate, topiiramate, topieamate, topiramaye, topiramwte, topiramatf, t9piramate, topirmate.
Topiramate reduces anxiety, buy topiramate, topiramate drug interactions, topiramate cognitive and topamax and anxiety topiramate. Topiramate fact sheet, compounding topiramate suspension, topiramate more for_patients and topiramate side effects dose or topiramate and zonisamide.
Topiramate controlled release
Gastric anastomosis ulcer, dermabrasion columbus ohio, ehlers danlos syndrome cleveland clinic, citalopram package insert and terazosin and levitra. Encapsulated urease positive mucoid red colonies, loxitane side effects, bursae body and pathophysiology of acute respiratory disease or phenergan prescribing information.
|
